Skip to main content

Type 2 diabetes

Gastrointestinal disorders

22-06-2022 | SGLT2 inhibitors | News

SGLT1/2 inhibitor shows early promise in NASH

The SGLT1/2 inhibitor licogliflozin has reduced liver enzyme levels in people with nonalcoholic steatohepatitis in a phase 2 trial published in Nature Medicine.

05-06-2022 | ADA 2022 | Conference coverage | News

Almost any liver fat may be abnormal

Researchers report that metabolic abnormalities begin to increase at levels of liver fat commonly regarded as normal.

Overweight person and injection pen

27-04-2022 | Tirzepatide | News

Tirzepatide reduces liver fat, improves time in range

The publication of two SURPASS-3 substudies in The Lancet Diabetes & Endocrinology reveals significant benefits of tirzepatide on liver and abdominal fat in people with type 2 diabetes, as well as on time in target glucose range.

04-02-2022 | Non-alcoholic fatty liver disease | News

Doctors call for NAFLD care pathway in type 2 diabetes

Physicians feel that nonalcoholic fatty liver disease is sidelined in type 2 diabetes management and should be formally incorporated into routine primary care pathways, say Australian researchers.

06-01-2022 | Pathogenesis | News

Genetic study backs role for liver fat, pancreatic volume in type 2 diabetes risk

A genetic propensity for increased liver fat and lower pancreatic volume is associated with an increased risk for type 2 diabetes, say researchers.

29-11-2021 | Metabolic surgery | News

Rival gastric surgery approaches have similar effects on liver fat

Gastric bypass and sleeve gastrectomy both result in “almost complete clearance of liver fat” within a year after the intervention, show secondary outcomes of a randomized trial.

09-09-2021 | Non-alcoholic fatty liver disease | News

Fatty liver index may predict progression to type 2 diabetes

The degree of non-alcoholic fatty liver disease, estimated by fatty liver index, is significantly associated with the risk for progression to type 2 diabetes in people with prediabetes, Spanish study findings indicate.

08-01-2021 | Non-alcoholic fatty liver disease | News

Liver fibrosis common in type 2 diabetes

Researchers have detected moderate or severe liver fibrosis in around one in six people with type 2 diabetes.

13-11-2020 | Semaglutide | News

Semaglutide treatment may reverse NASH

Treatment with semaglutide can lead to resolution of nonalcoholic steatohepatitis in people with or without type 2 diabetes, show phase 2 trial findings, although a question mark remains over its effect on fibrosis.

18-09-2020 | Dulaglutide | News

Add-on dulaglutide may reduce liver fat in people with type 2 diabetes, NAFLD

Results from the D-LIFT trial suggest a reduction in liver fat content when dulaglutide, a glucagon-like peptide-1 receptor agonist, is added to standard care treatment in people with concurrent type 2 diabetes and non-alcoholic fatty liver disease.

Gastric bypass surgery (used with permission)

12-08-2019 | Metabolic surgery | Highlight | News

Bariatric surgery linked to late adverse events

People who undergo bariatric surgery have a lower long-term risk for mortality, but a higher risk for adverse events such as gastrointestinal and nutritional disorders, compared with those who do not undergo surgery, researchers report.

Read the linked commentary from John Wilding

24-05-2019 | Non-alcoholic fatty liver disease | News

Diabetes patients at high risk of serious NAFLD outcomes

People with non-alcoholic fatty liver disease or non-alcoholic steatohepatitis are at particularly high risk for progression to cirrhosis or hepatocellular carcinoma if they have diabetes, say researchers.

05-12-2018 | Non-alcoholic fatty liver disease | Article

A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?

Lonardo A, Lugari S, Ballestri S et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1266-0

22-06-2018 | Gastroparesis | Review | Article

Diabetic gastroparesis: Principles and current trends in management

Krishnasamy S, Abell TL. Diabetes Ther (2018); 9 (Suppl 1): 1. doi: 10.1007/s13300-018-0454-9

20-03-2018 | Diet | News

DiRECT: Effects on insulin and liver fat revealed

Researchers from the DiRECT trial have reported large positive effects on liver fat and insulin secretion among people who achieved type 2 diabetes remission in response to a very-low-calorie diet.

Blood test results

07-02-2018 | Risk factors | Highlight | News

‘Subtle’ metabolic derangement seen decades before diabetes diagnosis

Research shows that changes in markers of the metabolic syndrome and fatty liver disease are present more than 20 years before people receive a diagnosis of type 2 diabetes.

29-12-2017 | Nephropathy | Review | Article

Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus

Nat Rev Endocrinol 2017; 14: 99–114. doi: 10.1038/nrendo.2017.173

27-10-2017 | Risk factors | Review | Article

Diabetes and the pancreatobiliary diseases

Shafqet M, Sharzehi K. Curr Treat Options Gastro 2017; 15: 508–519. doi: 10.1007/s11938-017-0163-x

06-10-2017 | Gastrointestinal disorders | Article

Screening for celiac disease in poorly controlled type 2 diabetes mellitus: Worth it or not?

Kizilgul M et al. BMC Endocr Disord 2017; 17: 62. doi: 10.1186/s12902-017-0212-4